A Phase 2 Study of Duvelisib Efficacy and Safety in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Previously Treated with a Brutons Tyrosine Kinase Inhibitor (BTKi)
Study of Drug in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Sponsor: Verastem, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR6847
U.S. Govt. ID: NCT03370185
Contact: Nicole Lamanna, MD: 646-317-5205 / nl2129@cumc.columbia.edu
Additional Study Information: The main goal of this study is to find out about how duvelisib acts in patients with CLL/SLL who were previously treated with a BTKi (Bruton Tyrosine Kinase inhibitor - commercially available ibrutinib or another investigational BTKi). Duvelisib is an investigational drug, meaning that it is not FDA approved, designed to try to stop cancer growth by blocking PI3 kinase activity. PI3 kinase is an enzyme in the body that is overproduced by some cancers, can fuel cancer growth and is known to be increased in many blood cancers.
This study is closed
Investigator
Nicole Lamanna, MD
Do You Qualify?
Are you at least 18 years of age? Yes No
Do you have a diagnosis of CLL or SLL? Yes No
Have you received at least one prior therapy for CLL or SLL? Yes No
Was your prior therapy BTKi therapy? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Nicole Lamanna, MD
nl2129@cumc.columbia.edu
646-317-5205
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE